NCT07214922View on ClinicalTrials.gov

Relative Bioavailability of Evobrutinib Tablet Batches

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

January 18, 2023

Primary Completion Date

February 24, 2023

Study Completion Date

February 24, 2023

Conditions
Healthy
Interventions
DRUG

Treatment A

Participants will receive single dose of Treatment A in treatment period 1, 2, 3 or 4 under fasted conditions.

DRUG

Treatment B

Participants will receive single dose of Treatment B in treatment period 1, 2, 3 or 4 under fasted conditions.

DRUG

Treatment C

Participants will receive single dose of Treatment C in treatment period 1, 2, 3 or 4 under fasted conditions.

DRUG

Treatment D

Participants will receive single dose of Treatment D in treatment period 1, 2, 3 or 4 under fasted conditions.

Trial Locations (1)

89231

Nuvisan GmbH, Neu-Ulm

All Listed Sponsors
lead

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

INDUSTRY